GoodRx vs. Hims & Hers Health: Stagnation vs. Growth in Revenue
Key Points
Hims & Hers Health currently leads the revenue comparison against GoodRx, displaying continuous upward momentum across recent reporting periods.
GoodRx has experienced a relatively flat quarter-over-quarter revenue pattern throughout the observed period, whereas Hims & Hers Health has shown consistent, sequential growth.
Investors should watch whether the widening revenue gap between the two companies continues to expand or begins to stabilize in upcoming quarters.
- 10 stocks we like better than GoodRx ›
GoodRx: Flat Revenue Trends
GoodRx (NASDAQ:GDRX) primarily generates revenue by offering a price comparison tool that helps consumers find geographically relevant pricing and access negotiated discounts on prescription drugs across the United States.
While expanding its offerings to include new weight-loss medications and navigating a rejected privacy settlement in federal court, it reported about 21% EBIT margin for the quarter ended Dec. 31, 2025.
Hims & Hers Health: Sequential Revenue Growth
Hims & Hers Health (NYSE:HIMS) earns its revenue by operating a telehealth network that connects consumers to licensed healthcare professionals, providing medical consultations and ongoing prescription medication subscriptions directly to customers.
It shifted its strategy to collaborate with a major pharmaceutical manufacturer and faced several shareholder investigations, while generating approximately 72% gross margin for the quarter ended Dec. 31, 2025.
Why Revenue Matters for Retail Investors
Revenue here refers to the data provider's standardized income-statement revenue line item, and it serves as a straightforward indicator of overall consumer demand that helps investors evaluate whether a business is successfully attracting and retaining users.
Quarterly Revenue for GoodRx and Hims & Hers Health
| Quarter (Period End) | GoodRx Revenue | Hims & Hers Health Revenue |
|---|---|---|
| Q1 2024 (March 2024) | $197.9 million | $278.2 million |
| Q2 2024 (June 2024) | $200.6 million | $315.6 million |
| Q3 2024 (Sept. 2024) | $195.3 million | $401.6 million |
| Q4 2024 (Dec. 2024) | $198.6 million | $481.1 million |
| Q1 2025 (March 2025) | $203.0 million | $586.0 million |
| Q2 2025 (June 2025) | $203.1 million | $544.8 million |
| Q3 2025 (Sept. 2025) | $196.0 million | $599.0 million |
| Q4 2025 (Dec. 2025) | $194.8 million | $617.8 million |
Data source: Company filings.
Foolish Take
The top-line stagnation that has been frustrating GoodRX investors did not improve during the first three months of 2026. On May 6, the medication savings platform reported first-quarter sales that declined by 4.4% year over year to $194 million.
Revenue dropped, but GoodRx’s pharma direct business is encouraging investors. The stock rose more than 10% following its first-quarter report. Shareholders seem pleased with an 82% year-to-year gain for the company’s Pharma Direct business. At $52 million, the Pharma Direct business is responsible for about 27% of total revenue.
With the average annual cost for a family health plan reaching $27,000 in 2026, fewer Americans have access to a primary care physician. The rising cost of traditional access to prescription drugs has been a strong tailwind for Hims & Hers Health’s alternative platform.
His & Hers will announce first-quarter results on May 11, 2026. In the fourth quarter of 2025, the company reported 13% year over year subscriber growth. With fourth-quarter revenue that surged 59% year over year, it’s clearly outperforming GoodRx.
Should you buy stock in GoodRx right now?
Before you buy stock in GoodRx, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and GoodRx wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $471,827!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,319,291!*
Now, it’s worth noting Stock Advisor’s total average return is 986% — a market-crushing outperformance compared to 207% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 10, 2026.
Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends GoodRx. The Motley Fool has a disclosure policy.
Recommended Articles
